Skip to main content
Quest Diagnostics

Cost-Effectiveness Analysis of Blood-Based Biomarker Testing in the Diagnosis of Alzheimer’s Disease Pathology

Cost-Effectiveness Analysis of Blood-Based Biomarker Testing in the Diagnosis of Alzheimer’s Disease Pathology

Authors: Li Y, Lagier RJ, Racke MK, Fesko YA

Citation: J Prev Alzheimers Dis. 2026 Jan 14;13(3):100474. doi: 10.1016/j.tjpad.2025.100474. Online ahead of print.

Specialties: Neurology

Download key summary

Related content

On-Demand Webinar
The Evolving Role of Biomarkers in Alzheimer’s Evaluation
Audio Podcast
Integrating Blood-Based Biomarkers for Alzheimer’s Risk Assessment
Test FAQ
Quest Dementia Testing
Publication
Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology
On-Demand Webinar
Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification
Publication
Clinical Utility of Plasma Aβ42/40 Ratio by LC-MS/MS in Alzheimer’s Disease Assessment
Conference Presentation
Analytical Performance of the Quest AD-Detect® Phosphorylated tau217 (p-tau217) Assay in Plasma

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.